0001104659-20-010940 4 1 20200131 20200205 20200205 Bruck Claudine 0001733680 4 34 001-39202 20576282 4995 BRADENTON AVE, SUITE 240 DUBLIN OH 43017-3552 Annovis Bio, Inc. 0001477845 2834 262540421 DE 1231 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 QR Pharma, Inc. 20091202 4 1 a4.xml 4 X0306 4 2020-01-31 0 0001477845 Annovis Bio, Inc. ANVS 0001733680 Bruck Claudine C/O ANNOVIS BIO, INC. 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 1 0 0 0 Common Stock 2020-01-31 4 P 0 800 6.00 A 800 D Common Stock 2020-01-31 4 C 0 3969 A 4769 D Common Stock 2020-01-31 4 C 0 1117 4.80 A 5886 D Series A-1 Preferred Stock 2020-01-31 4 C 0 5556 0 D Common Stock 3969 0 D Convertible Note 2020-01-31 4 C 0 1117 4.80 D Common Stock 1117 0 D The reporting person acquired these shares in the initial public offering ("IPO") of Annovis Bio, Inc. ("Annovis"). Each share of Series A-1 Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143. The convertible notes have a maturity date of December 31, 2023. The Convertible Notes automatically converted into common stock of Annovis upon the closing of the IPO at a conversion rate equal to the principal amount of the note, plus accrued and unpaid interest, divided by $4.80 (80% of the IPO price). /s/ Claudine Bruck 2020-02-04